Nantahala Capital Management

Portfolio Managers Wil Harkey and Dan Mack share responsibility for the portfolio. The firm's website notes the two have worked together for over 16 years and have a combined track record exceeding 19 years in small and micro-cap investing. No other investment professionals are publicly named in a decision-making capacity.

Nantahala focuses on a universe of companies below $2.5 billion in market capitalization — a segment many larger funds are structurally excluded from due to liquidity constraints and minimum position-size rules. The firm's long-term, partnership-oriented approach is designed to make it an attractive investor for micro-cap management teams, which can assist in proprietary origination. Its multi-office footprint across US and international cities may also support direct company engagement and research coverage in areas with sparse sell-side attention.

Nantahala runs a long/short, market-neutral strategy. The firm explicitly states it targets 'little to no equity market exposure,' constructing a portfolio where long and short positions are designed to offset directional market risk. This means returns are driven by stock-specific alpha in both directions rather than broad equity market performance.

The firm applies what it calls a 'PE-style investment approach,' taking a multi-year view on its holdings. Rather than trading around earnings prints, Nantahala seeks to partner with portfolio companies for extended periods. This long-duration posture is well-suited to micro-cap names where entry and exit can take months to execute without moving prices and where underlying business transformations unfold over years, not quarters.

Nantahala's public materials specifically call out smaller healthcare companies, describing the sector as 'in distress' and presenting what the firm views as extremely wide and nonsensical valuation disparities. While the strategy is not exclusive to healthcare, the firm signals it as an area where its research depth and long-term horizon are particularly relevant given the complexity and binary-outcome risk common in micro-cap biotech and medical-device names.

No. The firm does not publish AUM figures or headcount numbers on its website. This non-disclosure is notable in a peer set where many small-cap managers use publicly stated growth as a marketing signal and may reflect a deliberate effort to avoid attracting attention to its capacity, which is inherently limited in the micro-cap space.

Capacity is the primary structural edge. A multi-billion-dollar multi-strat firm cannot meaningfully allocate to sub-$2.5 billion companies without rapid position-size constraints and unintended beta. Nantahala is built exclusively for this end of the market, meaning its entire research process, trade-construction framework, and partnership-development approach are purpose-built for an opportunity set that larger peers can only dip into opportunistically, if at all.